Palisade Bio Inc (PALI)

Currency in USD
1.010
-0.010(-0.98%)
Closed·
After Hours
1.030+0.020(+1.98%)
·
PALI Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
PALI is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
0.9851.080
52 wk Range
0.6004.318
Key Statistics
Prev. Close
1.02
Open
1.01
Day's Range
0.985-1.08
52 wk Range
0.6-4.318
Volume
168.04K
Average Volume (3m)
646.23K
1-Year Change
-72.33%
Book Value / Share
1.21
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
PALI Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
10.667
Upside
+956.11%
Members' Sentiments
Bearish
Bullish
ProTips
2 analysts have revised their earnings upwards for the upcoming period

Palisade Bio Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell

Palisade Bio Inc Company Profile

Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases. The company’s lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor that is in phase 1a/b clinical trial for the treatment of ulcerative colitis, as well as under phase 1a clinical trial for the treatment of fibrostenotic crohn’s disease. It has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; a license agreement with the Regents of the University of California for sole purpose of maintaining the Newsoara Co-Development; and a co-development and distribution agreement with Newsoara Biopharma Co., Ltd. The company is headquartered in Carlsbad, California.

Compare PALI to Peers and Sector

Metrics to compare
PALI
Peers
Sector
Relationship
P/E Ratio
−0.4x−4.7x−0.5x
PEG Ratio
0.000.020.00
Price/Book
0.9x2.2x2.6x
Price / LTM Sales
-9.7x3.2x
Upside (Analyst Target)
-113.3%45.7%
Fair Value Upside
Unlock−5.8%8.6%Unlock

Analyst Ratings

3 Buy
0 Hold
0 Sell
Ratings:
3 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 10.667
(+956.11% Upside)

Earnings

Latest Release
May 12, 2025
EPS / Forecast
-0.47 / -0.48
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

PALI Income Statement

People Also Watch

15.91
SRPT
-3.11%
0.92
KLTO
-4.55%
7.570
TRON
-10.73%
2.56
INMB
-6.23%
168.10
CRCL
-8.40%

FAQ

What Stock Exchange Does Palisade Bio Trade On?

Palisade Bio is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Palisade Bio?

The stock symbol for Palisade Bio is "PALI."

What Is the Palisade Bio Market Cap?

As of today, Palisade Bio market cap is 4.84M.

What Is Palisade Bio's Earnings Per Share (TTM)?

The Palisade Bio EPS (TTM) is -5.42.

From a Technical Analysis Perspective, Is PALI a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.

How Many Times Has Palisade Bio Stock Split?

Palisade Bio has split 5 times.

How Many Employees Does Palisade Bio Have?

Palisade Bio has 8 employees.

What is the current trading status of Palisade Bio (PALI)?

As of 02 Aug 2025, Palisade Bio (PALI) is trading at a price of 1.01, with a previous close of 1.02. The stock has fluctuated within a day range of 0.99 to 1.08, while its 52-week range spans from 0.60 to 4.32.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.